NVRO Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 0.62%, SMA50 4.11%, SMA200 0.97%). The stock’s 14-day RSI is 69.91 (firm momentum), while the ATR of 0.05 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -57.8% below its high and over 84.52% above its low.

The latest quarter delivered EPS of -$0.70. The next quarter is forecast at $nan. Next year's EPS is expected at $17.40. Nevro Corp. earnings surprise history is frequent misses against expectations. The quarter that ended May 06, 2025, missed forecasts by -23.08%. The prior quarter beat by -18.99%. Over the last six quarters, Apple has recorded several small beats. These include -50.0% in February 21, 2024.

Nevro Corp. has 37.86 million shares outstanding. The public float is 36.38 million shares, elevated short interest at 9.00% of float. This equals 2.93 million shares. The short ratio is 4.98 days. Institutional investors hold 113.82% of the float. Insiders own 2.84%. DEMANE MICHAEL F holds 231.28 thousand shares, GROSSMAN D KEITH has 169.29 thousand shares and Rashid Kashif has 53.53 thousand shares.

Nevro Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$18.95. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $3.17 and $13.30. With a market capitalization of about $224.09 million, Nevro Corp. is classified as a micro-cap and shows market-like volatility (beta ~0.82). Key stats such as the average daily volume over the past year has been around 1.30 million shares, volume is running light vs its 52-week average. Headquartered in Redwood City, CA, Nevro Corp. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Kevin R. Thornal, the company employs approximately 1,099 people and listed since November 06, 2014. Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally.

Nevro Corp. trades at a P/E ratio of -3.21, slightly below the S&P 500 average, with a price-to-sales ratio of 1.11 and a price-to-book ratio of 0.95 suggesting the stock is closer to book value. The P/FCF stands at 13.37, also above market averages.

Nevro Corp. (NYSE:NVRO) shares are up 56.99% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Nevro Corp. trading at a premium to the broader market with a P/E of -3.21. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $51.01, suggesting 773.46% upside. Our AI forecast model points to short-term strength (1.54% over two weeks), a medium-term rise (19.69% over three months), and a longer-term loss (-59.25% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Nevro Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.54%, with price expected at $5.93 by April 16, 2025, within a range of $5.87 to $6.01 3-Month Outlook: Projected rise of 19.69%, reaching $6.99 by July 01, 2025, with a range of $5.84 to $7.51. 1-Year Outlook: Projected loss of -59.25%, with price at $2.38 by April 02, 2026, within a range of $0.00 to $0.00.